It's the Dog Days of August, and Monday was National Dog Day. Of course, here at Mersana, we celebrate dog day all year round. Thanks to our furry co-workers for chasing deadlines and tennis balls! #TeamMersana #DogDays
Mersana Therapeutics
Biotechnology Research
Cambridge, MA 12,199 followers
Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fighting cancer.
About us
At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
- Website
-
http://www.mersana.com
External link for Mersana Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
- Founded
- 2001
- Specialties
- cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology
Locations
-
Primary
840 Memorial Drive
Cambridge, MA 02139, US
Employees at Mersana Therapeutics
Updates
-
Mersana's Green Team partnered with CitySprouts to adopt a local elementary school garden for the summer. We're keeping our promise to water, weed and harvest until Labor Day to keep the garden in good shape for the students' return in the fall! #TeamMersana #GoGreen
-
Mersana provided business updates and reported its Q2 results this morning. Read all about it here: https://lnkd.in/eMsNPsZ9 $MRSN
-
-
Mersana will be providing business updates and reporting its second quarter 2024 financial results next week. Be sure to tune into our conference call at https://lnkd.in/g_ym64R $MRSN
-
-
#TeamMersana had a phenomenal time together last week at our summer outing on the Charles River! Fun activities, delicious food, great company! #SummerFun
-
We are thrilled to recognize these 14 Mersana team members who were recently promoted. Thanks for your tremendous contributions and all that you continue to do to advance our mission! June Buchanan, MBA, Susan Clardy, Baher Daoud, Vaishali Dixit, Melissa Dolan, Roxanne Hasenfuss, Saumil Joshi, CISM, CISA, Lauren Kimball, David Moore, CPA, Jasmine Ng, Caroline Rogalski, Vandana S., Lei Zhu, Manghong Zhu, PhD #TeamMersana
-
Mersana Therapeutics reposted this
Science Club for Girls Board Former Co-Chair Alejandra Carvajal recently spoke about SCFG's mission and vision at our Catalyst Awards, reflecting on the impact that SCFG would have had on her growing up as young woman interested in STEM education and careers. "As the first one in my immigrant family to attend and graduate college, I see myself in our participants. When I was little, I dreamed of being an astronomer and if I had had access to a program like SCFG, I would have had more confidence to pursue an interest in science. It certainly would have counteracted the many social messages, both overt and unconscious, that I wasn't the kind of person who could succeed in science." -Alejandra Carvajal, SVP & Chief Legal Officer at Mersana Therapeutics, Inc. #girlsinstem #womeninstem #impact #TransformtheFaceofSTEM
-
-
Exciting to share this new publication in Nature describing the mechanism of action underlying Immunosynthen, Mersana's STING-agonist ADC platform! #Immunosynthen #AntibodyDrugConjugates https://rdcu.be/dNund
-
-
Great context from Mersana Chief Science & Technology Officer Timothy Lowinger in this #BioSpace article regarding the emergence and potential of immunostimulatory #AntibodyDrugConjugates. #Immunosynthen https://lnkd.in/eCzHw2PR
-
The #STINGPathway has been used in preclinical studies to trigger strong immune responses against tumors. Mersana’s XMT-2056, a #STINGAgonist #ADC, is being investigated in a Phase 1 trial for multiple solid tumors. https://lnkd.in/etnEVw4r #immunotherapy
-